Endogenex™ Announces $88 Million Series C Financing to Complete Pivotal Trial of the ReCET™ System in Patients with Type 2 Diabetes
- Written by PR Newswire
 |
Oversubscribed financing led by strategic investor, with participation from new and existing investors
MINNEAPOLIS, June 25, 2024 /PRNewswire/ -- Endogenex, a clinical-stage medical device company dedicated to improving outcomes in individuals with type 2 diabetes, announced it has closed an oversubscribed Series C financing totaling $88 million....
